UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA.

被引：0
|
作者：
Piris-Villaespesa, M. [1 ]
Chavez, J. [2 ]
Dalia, S. [2 ]
Veliz, M. [3 ]
Lancet, Jeffrey [2 ]
Bello, C. [2 ]
Turba, E. [2 ]
Shah, B. [2 ]
Komrokji, R. [2 ]
Sokol, L. [2 ]
Locke, F. [4 ]
Kharfan-Dabaja, M. [4 ]
Sotomayor, E. [2 ]
Pinilla-Ibarz, J. [2 ]
机构：
[1] Hosp Univ Puerta de Hierro Majadahonda, Hematol, Madrid, Spain
[2] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL USA
[3] Cent Florida Hematol Onc, Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Bone Marrow Transplant, Tampa, FL USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P108
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [1] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
    Chavez, Julio C.
    Piris-Villaespesa, Miguel
    Dalia, Samir
    Powers, John
    Turba, Elyce
    Nodzon, Lisa
    Komrokji, Rami
    Sokol, Lubomir
    Locke, Frederick L.
    Lancet, Jeffrey
    Sotomayor, Eduardo M.
    Kharfan-Dabaja, Mohamed A.
    Pinilla-Ibarz, Javier
    LEUKEMIA RESEARCH, 2016, 47 : 78 - 83
  • [2] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wen, Sijin
    Wierda, William G.
    O'Brien, Susan M.
    Faderl, Stefan
    Sargent, Rachel
    Burger, Jan A.
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) : 584 - 591
  • [3] Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.
    Maddocks, Kami
    Lapalombella, Rosa
    Blum, Kristie A.
    Blum, William
    Fischer, Beth B.
    Muthusamy, Natarajan
    Moran, Mollie E.
    Holtzapfel, Donna
    Byrd, John C.
    Johnson, Amy J.
    Andritsos, Leslie
    BLOOD, 2009, 114 (22) : 1339 - 1339
  • [4] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
    Chanan-Khan, Asher
    Miller, Kena C.
    Musial, Laurie
    Lawrence, David
    Padmanabhan, Swaminathan
    Takeshita, Kenichi
    Porter, Carl W.
    Goodrich, David W.
    Bernstein, Zale P.
    Wallace, Paul
    Spaner, David
    Mohr, Alice
    Byrne, Catriona
    Hernandez-Ilizaliturri, Francisco
    Chrystal, Cynthia
    Starostik, Petr
    Czuczman, Myron S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5343 - 5349
  • [5] The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.
    Ferrajoli, Alessandra
    Badoux, Xavier
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lerner, Susan
    Kantarjian, Hagop
    Keating, Michael J.
    BLOOD, 2010, 116 (21) : 600 - 600
  • [6] A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Castro, Januario E.
    Olivier, Loria J.
    Robier, Aguillon A.
    Danelle, James
    Carlos, Suarez J.
    Bi-Ying, Yeh
    Thomas, Kipps J.
    BLOOD, 2006, 108 (11) : 803A - 803A
  • [7] Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)
    Ryan, Christine E.
    Crombie, Jennifer L.
    Tyekucheva, Svitlana
    McDonough, Mikaela M.
    Montegaard, Josie S.
    Kim, Austin, I
    Soumerai, Jacob D.
    Alencar, Alvaro J.
    Bhandari, Shruti
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2022, 140 : 9871 - 9872
  • [8] Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Badoux, Xavier C.
    Keating, Michael J.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lerner, Susan
    Sargent, Rachel L.
    Kantarjian, Hagop M.
    Ferrajoli, Alessandra
    BLOOD, 2011, 118 (21) : 448 - 448
  • [9] Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis
    Choi, Michael Y.
    Castro, Januario E.
    Hoff, Sheila
    Li, Hongying
    Rassenti, Laura
    James, Danelle F.
    Messer, Karen
    Kipps, Thomas J.
    BLOOD, 2013, 122 (21)
  • [10] Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
    Wendtner, Clemens-Martin
    Hillmen, Peter
    Mahadevan, Daruka
    Buehler, Andreas
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David D.
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    Moutouh-de Parseval, Laure
    Hallek, Michael
    Heerema, Nyla A.
    Stilgenbauer, Stephan
    Chanan-Khan, Asher A.
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 417 - 423
12345